TAMPA, Fla. and LONDON, March 17, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice ...
Akari Therapeutics, a biotechnology company focused on developing precision bi-functional antibody drug conjugates (ADCs) for cancer treatment, announced its participation in the Virtual Investor “Top ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results